Literature DB >> 22188360

Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

Stuart A Scott1, Manishkumar Patel, Suparna Martis, Steven A Lubitz, Sarina van der Zee, Chang Yoo, Lisa Edelmann, Jonathan L Halperin, Robert J Desnick.   

Abstract

AIM: To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of warfarin. PATIENTS &
METHODS: DNA samples from 178 patients were subjected to copy number analyses by multiplex ligation-dependent probe amplification or quantitative PCR assays. Additionally, the CYP2C9 exon 8 insertion/deletion polymorphism (rs71668942) was examined among the patient cohort and 1750 additional multiethnic healthy individuals.
RESULTS: All patients carried two copies of CYP2C9 by multiplex ligation-dependent probe amplification and no exon 8 deletion carriers were detected. Similarly, quantitative PCR assays for VKORC1, CYP4F2, GGCX and CALU identified two copies in all populations.
CONCLUSION: These data indicate that copy number variants in the principal genes involved in warfarin dose variability (CYP2C9, VKORC1), including genes with lesser effect (CYP4F2, GGCX), and those that may be more relevant among certain racial groups (CALU), are rare in multiethnic populations, including African-Americans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22188360      PMCID: PMC3292047          DOI: 10.2217/pgs.11.156

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  66 in total

1.  Segmental duplications and copy-number variation in the human genome.

Authors:  Andrew J Sharp; Devin P Locke; Sean D McGrath; Ze Cheng; Jeffrey A Bailey; Rhea U Vallente; Lisa M Pertz; Royden A Clark; Stuart Schwartz; Rick Segraves; Vanessa V Oseroff; Donna G Albertson; Daniel Pinkel; Evan E Eichler
Journal:  Am J Hum Genet       Date:  2005-05-25       Impact factor: 11.025

2.  A high-resolution survey of deletion polymorphism in the human genome.

Authors:  Donald F Conrad; T Daniel Andrews; Nigel P Carter; Matthew E Hurles; Jonathan K Pritchard
Journal:  Nat Genet       Date:  2005-12-04       Impact factor: 38.330

Review 3.  Copy number variants and pharmacogenomics.

Authors:  Karim Ouahchi; Neal Lindeman; Charles Lee
Journal:  Pharmacogenomics       Date:  2006-01       Impact factor: 2.533

Review 4.  Oral anticoagulant drugs.

Authors:  J Hirsh
Journal:  N Engl J Med       Date:  1991-06-27       Impact factor: 91.245

5.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

Authors:  M Wadelius; L Y Chen; K Downes; J Ghori; S Hunt; N Eriksson; O Wallerman; H Melhus; C Wadelius; D Bentley; P Deloukas
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

6.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Authors:  Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles S Eby; Howard L McLeod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

7.  An initial map of insertion and deletion (INDEL) variation in the human genome.

Authors:  Ryan E Mills; Christopher T Luttig; Christine E Larkins; Adam Beauchamp; Circe Tsui; W Stephen Pittard; Scott E Devine
Journal:  Genome Res       Date:  2006-08-10       Impact factor: 9.043

8.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

9.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Authors:  Elizabeth A Sconce; Tayyaba I Khan; Hilary A Wynne; Peter Avery; Louise Monkhouse; Barry P King; Peter Wood; Patrick Kesteven; Ann K Daly; Farhad Kamali
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

10.  Global variation in copy number in the human genome.

Authors:  Richard Redon; Shumpei Ishikawa; Karen R Fitch; Lars Feuk; George H Perry; T Daniel Andrews; Heike Fiegler; Michael H Shapero; Andrew R Carson; Wenwei Chen; Eun Kyung Cho; Stephanie Dallaire; Jennifer L Freeman; Juan R González; Mònica Gratacòs; Jing Huang; Dimitrios Kalaitzopoulos; Daisuke Komura; Jeffrey R MacDonald; Christian R Marshall; Rui Mei; Lyndal Montgomery; Kunihiro Nishimura; Kohji Okamura; Fan Shen; Martin J Somerville; Joelle Tchinda; Armand Valsesia; Cara Woodwark; Fengtang Yang; Junjun Zhang; Tatiana Zerjal; Jane Zhang; Lluis Armengol; Donald F Conrad; Xavier Estivill; Chris Tyler-Smith; Nigel P Carter; Hiroyuki Aburatani; Charles Lee; Keith W Jones; Stephen W Scherer; Matthew E Hurles
Journal:  Nature       Date:  2006-11-23       Impact factor: 49.962

View more
  10 in total

Review 1.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

Review 2.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

Review 3.  Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine.

Authors:  Brittney H Davis; Nita A Limdi
Journal:  Clin Pharmacol Ther       Date:  2021-07-29       Impact factor: 6.903

4.  Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients.

Authors:  Shahdah Khosropanah; Seyed Nooreddin Faraji; Hamzeh Habibi; Majid Yavarian; Roohollah Mansoori; Sezaneh Haghpanah
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

5.  Copy number variation profiling in pharmacogenetics CYP-450 and GST genes in Colombian population.

Authors:  Brian Ramírez; María José Niño-Orrego; Daniel Cárdenas; Kevin Enrique Ariza; Karol Quintero; Nora Constanza Contreras Bravo; Caroll Tamayo-Agudelo; María Alejandra González; Paul Laissue; Dora Janeth Fonseca Mendoza
Journal:  BMC Med Genomics       Date:  2019-07-19       Impact factor: 3.063

6.  Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation.

Authors:  Yan Wang; Min Chen; Hui Chen; Fang Wang
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

7.  Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial.

Authors:  Qing Kong; Yuxue Cao; Zhen Gao; Jing Sun; Hongying Zhang; Yijie Du; Yubao Lv; Sihan Zhou; Zihui Tang; Baojun Liu; Jingcheng Dong
Journal:  Trials       Date:  2022-02-14       Impact factor: 2.279

8.  Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang.

Authors:  Xiayizha Kamali; Muhuyati Wulasihan; Yu-Chun Yang; Wu-Hong Lu; Zhi-Qiang Liu; Peng-Yi He
Journal:  Lipids Health Dis       Date:  2013-10-23       Impact factor: 3.876

Review 9.  A review of a priori regression models for warfarin maintenance dose prediction.

Authors:  Ben Francis; Steven Lane; Munir Pirmohamed; Andrea Jorgensen
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

10.  Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm.

Authors:  Lin Pei; Xiaoyi Tian; Yan Long; Wenhui Nan; Mei Jia; Rui Qiao; Jie Zhang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.